Satsuma Pharmaceuticals has raised $62 million in a Series B preferred stock financing, led by Wellington Management Company.
Other existing investors in this Series B funding included RA Capital Management, TPG Biotech and Shin Nippon Biomedical. Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures and SBI Investment were new investors.
Get the full story on our sister site, Drug Delivery Business.